US Senator Bernie Sanders has said he plans to hold a vote on 31st January to subpoena the chief executives of Johnson & Johnson and Merck & Co for a hearing on dr
Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr
Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protection in July
The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD.
A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent
Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.